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Abstract
Purpose of review—To describe the current knowledge on the cross-talk between connexins 
and microRNAs (miRs) in bone cells.
Recent findings—Connexins play a crucial role on bone development and maintenance, and 
disruptions in their abundance or localization can affect how bone perceives and responds to 
mechanical, hormonal, and pharmacological stimuli. Connexin expression can be modified by 
miRs, which modulate connexin mRNA and protein levels. Recently, different manners by which 
miRs and connexins can interact in bone have been identified, including mechanisms that mediate 
miR exchange between cells in direct contact through gap junctions, or between distant cells via 
extracellular vesicles (EVs).
Summary—We bring to light the relationship between miRs and connexins in bone tissue, with 
special focus on regulatory effects of miRs and connexins on gene expression, as well as the 
mechanisms that mediate miR exchange between cells in direct contact through gap junctions, or 
between distant cells via EVs.
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Introduction
The evolution from unicellular to multicellular organisms was an enormous step in the 
advancement of organism development, requiring a system to coordinate the exchange of 
molecules among cells and the generation of a vast array of membrane specializations. In 
particular, skeletal development and homeostasis depends on the tight control of bone cell 
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proliferation, differentiation and activity, orchestrated through regulated cell-to-cell 
communication [1–3]. This coordinated intercellular communication via the exchange of 
signaling molecules and genetic material can occur between adjacent cells in direct contact 
through gap junction channels formed by connexins [4,5] or between distant cells via 
extracellular vesicle- (EV) mediated signaling [6]. Intercellular microRNA (miR) transfer 
has recently been shown to play a critical role in regulating a variety of key cellular 
processes involved in the maintenance of skeletal tissue [7]. Herein, we will discuss the 
complex regulatory signaling mechanisms involved in controlling bone cells through 
intracellular bidirectional miR and connexin post-translational regulation, as well as 
intercellular signaling via diverse mechanisms of miR transfer.
Gap junctions: structure and function
Gap junctions, a type of membrane specialization, are clusters of membrane channels that 
enable electrometabolic coupling and control the passage of ions, such as Ca2+, H+, Na+, 
K+, Cl−, sugars, amino acids, nucleotides, and vitamins up to 1.5 nm in diameter through 
conduit-like structures named connexons [8]. In addition, recent findings have shown that 
larger biomolecules, such as nucleic acids, can also go through these channels [4].
Gap junction proteins or connexins contain four transmembrane domains, two extracellular 
loops, cytoplasmic N- and C-terminal domains, and a single cytoplasmic loop. Connexins 
are named based on their expected molecular weight; for example, connexin (Cx) 43 and 
Cx37 are approximately 43 and 37 kDa in size, respectively [8,9]. Six connexin molecules 
assemble in the Golgi apparatus to form a connexon (or hemichannel) that is then 
transported to the plasma membrane, where it is coupled to another connexon of an adjacent 
cell, forming a continuous aqueous channel between the cells [10]. In addition to mediating 
the exchange of molecules between cells, connexins can also participate in intracellular 
signaling by triggering biochemical signals through their structural domains [11].
While connexins are expressed in nearly every cell type, with the exception of red blood 
cells, spermatozoids, and differentiated skeletal muscle cells of adult vertebrates, the 
composition and cellular membrane quantity of gap junction channels varies greatly between 
cell types [8]. Connexin expression and channel activity is controlled by numerous 
regulatory factors. To ensure proper activity, the control of opening and closure of the 
channels is regulated by voltage, ion concentration, cytoplasmic pH, amino sulfonates, 
phosphorylation, lipophiles, cyclic nucleotides, and others [9], although the precise 
mechanisms are not completely known. In addition, the half-life of the intercellular gap 
junctions is only a couple of hours, undergoing degradation in the endo-lysosomal network 
about 10 times faster than other membrane proteins [8]. The rapid turnover allows for the 
dynamic and efficient regulation of connexin abundance and localization, which facilitates 
the rapid exchange of molecules and downstream signaling upon cell requirement. Further, 
gap junction protein expression and activity are also controlled by several post-translational 
mechanisms, including phosphorylation, oxidation/reduction, protein-protein interaction, 
and regulation of mRNA/protein levels by small noncoding RNA, particularly miRs.
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The essential role that connexins play in the development and maintenance of bone cells has 
been demonstrated in numerous studies [12]. Cx43 was the first connexin to be identified 
and it is the most highly studied and expressed connexin in bone tissue. Mutations of the 
Cx43 gene are associated with occulodentodigital dysplasia (ODDD), a disorder 
characterized by abnormalities that include weak enamel, small or missing teeth, early tooth 
loss, and broad long bones [13]. Although Cx45 and Cx46 are also expressed in bone 
[14,15], their role is still unknown. Global Cx40-deficient newborn mice show defective 
axial and appendicular bone, with abnormal rib development, lower limb malformations and 
delayed ossification in anklebones [16]. This phenotype is due to abnormal endochondral 
ossification, and the role of Cx40 in adult bone is not known. More recently, Cx37 deletion 
was associated with reduced osteoclastogenesis and modifications in bone geometry and 
Wnt/β-catenin signaling [17,18].
Cx43 expression in osteoblasts and osteocytes is important for proper bone development and 
health. Thus, analysis of embryos with global Cx43 deletion shows delayed bone formation 
and defective osteoblast differentiation, which affects both endochondral and 
intramembranous bone formation [19]. Milder skeletal phenotypes are observed in mice 
lacking Cx43 in osteochondroprogenitors, osteoblast precursors, and mature osteoblasts, 
which is progressively less evident as the connexin is deleted in more mature cells [20]. 
Further, Cx43 targeted deletion in osteocytes does not alter bone mineral density, but results 
in osteocyte apoptosis and modifications in the composition of the bone matrix and bone 
mechanical properties. In addition, osteoclast differentiation is impaired in mice lacking 
Cx43 in osteoclast precursors, resulting in reduced bone resorption [21]. Thus, all these 
pieces of evidence point out that the fine-tuned control of gap junction/connexin expression 
is crucial for bone health.
microRNA biogenesis, structure, and function
miRs are a class of small noncoding RNA gene products of approximately 22 nucleotides in 
length that function in the post-transcriptional regulation of gene expression in diverse 
organisms, including plants and animals [22]. Since their first description in 1993, thousands 
of new miRs have been discovered [23]. miRs are named using the “miR” prefix along with 
an exclusive identification number (for example, miR-21, miR-218, miR-5, etc.), which 
follows the order in which that miR was described. However, there are a few exceptions such 
as the names for let-7 and lin-4, which are maintained for historical reasons. The gene name 
encoding the miR receives the same three-letter prefix [24].
miR biogenesis is a complex biological process that involves multiple steps and requires 
numerous transcription factors, binding-proteins, and regulatory enzymes (Fig. 1). miRs are 
encoded in long endogenous transcripts that are transcribed as long primary transcripts 
(primiRs), which form a long single-molecule hairpin structure [22]. Pri-miRs then undergo 
a specific enzymatic cleavage driven by the microprocessor complex composed of Drosha 
and DGCR8, which generates a shorter hairpin structure precursor miR (pre-miRs). 
Following cleavage, the pre-miR is exported by exportin-5 from the nucleus to the 
cytoplasm, where it undergoes additional cleavage by Dicer into a mature miR duplex [25]. 
Upon loading onto an argonaute (AGO) protein, one strand is lost whereas the other 
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complementary miR strand is incorporated into the RNA-induced silencing complex (RISC) 
where the miR and the corresponding messenger RNA interact. Specifically, miRs bind to 
the 3′- or 5′- untranslated regions (UTR) of mRNAs inducing repression of gene expression 
in a complementarity-dependent level. One single miR might target several genes, whereas 
several miRs can target a single gene [22].
Extensive research across numerous fields has demonstrated the important role of miRs in 
regulating many essential biological processes including tissue development, and cell 
differentiation, activity, and survival, as well as in the onset and progression of numerous 
diseases in various tissues [26]. In particular, miRs have been shown to play an important 
role in the process of skeletal development and bone remodeling under physiological 
conditions and in metabolic bone diseases, including osteoporosis [27–29]. The role of miRs 
in skeletal development was first demonstrated by in vivo studies in which Dicer was deleted 
in bone cells, which resulted in an overall reduction in miR expression. These decreases in 
miR expression led to significant growth and skeletal defects, as a consequence of 
reductions in proliferation and differentiation of chondrocytes and osteoblasts [29]. 
Moreover, a variety of miRs have been shown to play a role in bone remodeling by 
regulating osteoblast and osteoclast differentiation, activity and survival [29,30]. Although 
the critical role of miRs in regulating bone development and homeostasis has been 
demonstrated by numerous studies, the mechanisms of their action and their roles in bone 
cell signaling still remain unclear.
Recent studies have demonstrated that miRs generated in one cell can be transferred and 
regulate mRNA expression in neighboring or distant cells through different mechanisms, 
which include connexin channel-mediated transfer, as well as EV-directed transport, 
illustrated in Fig. 1 [6,31,32].
Extracellular vesicles
Extracellular vesicles (EVs) made up of organelle-free cytosol surrounded by a lipid bilayer 
membrane are released from numerous cell types, including osteoblasts, osteocytes, and 
osteoclasts [33]; and have been recently shown to play an important role in mediating cell-
to-cell signaling [34–36]. EVs, which include exosomes (30-100 nm), microvesicles 
(50-2000 nm), and apoptotic bodies (500-5000 nm) are classified depending on their size 
and are formed and released through different mechanisms [35] (Fig. 1). Exosomes, the 
smallest type of EVs, are formed by a process involving the inward budding of the 
endosomal membrane leading to the formation of multivesicular bodies (MVB). Following 
fusion of the outer MVB membrane with the plasma membrane, the MVBs are then released 
into the extracellular space as exosomes [32]. Microvesicles and apoptotic bodies are formed 
through the outward budding of the plasma membrane [33]. The EV membrane provides a 
protective environment, maintaining the stability of the molecular cargo contained within the 
EV in the extracellular environment.
Upon extracellular release, EVs can mediate intercellular signaling through the transfer of 
their cargo, including proteins, lipids, mRNAs, and miRs, to neighboring or distant cells 
[37]. The recipient cell can take up EVs through a variety of different mechanisms such as 
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direct membrane fusion, clathrin-mediated endocytosis, phagocytosis and micropinocytosis, 
or receptor-ligand interactions [32] (Fig. 1). Further, recent work by Soares et al. found that 
Cx43 hemichannels are present on the exosomal surface and that these connexin channels 
can interact with connexin channels present on the plasma membranes of recipient cells 
facilitating the transfer of exosomal cargo to recipient cells [38]. The physiological relevance 
of this EV-mediated transfer in skeletal tissues has been demonstrated by regulation of bone 
remodeling by altering osteoblast and osteoclast differentiation and function following EV 
release and uptake between bone cells [7].
Cross-regulation of connexins and miRs in bone cells
Computational methods predict several RNA- and DNA-binding motifs present in the 
sequences of connexins [39]. Further, studies in recent years have shown that connexin 
expression is functionally regulated by miRs in bone cells. In particular, miR-206, initially 
considered as muscle-specific, is expressed in osteoblastic cells and is involved in the 
regulation of Cx43 expression [40]. Thus, Cx43 expression is repressed by osteoblastic-
targeted miR-206 overexpression in mice, resulting in low bone formation and reduced bone 
mass. Another study showed that miR-206 derived from cells of the hematopoietic and 
osteoblastic lineages is upregulated, whereas Cx43 expression is reduced in a rabbit model 
of glucocorticoid-induced osteonecrosis of the femoral head [41], further supporting the role 
of miR-206 as a bone miR that targets Cx43. miR-23a is also expressed in osteoblastic cells, 
and its overexpression in human osteosarcoma cells leads to downregulation of Cx43 
expression and inhibition of the increase in Cx43 expression during osteoblast differentiation 
[42]. Overexpression of miR-23a also is accompanied by delayed osteoblast differentiation, 
suggesting that the miR can inhibit osteoblastogenesis by repressing Cx43 expression. On 
the other hand, miR-211 expression is increased during osteogenic differentiation in human 
induced pluripotent stem cells, and transfection of a miR-211 inhibitor abrogated osteoblast 
differentiation and mineralization in vitro [43]. This study showed that the effect of miR-211 
on osteoblast differentiation is mediated by an increase in autophagy, downstream of 
upregulation of Atg14 expression. Although Cx43 expression has been shown to regulate 
autophagy in osteoblastic cells and to associate with Atg14 in the absence of serum [44], it is 
not known whether the effect of miR-211/Atg14 in osteoblast differentiation is mediated by 
Cx43.
We have recently shown that bones from old mice exhibit reduced Cx43 expression, and that 
miR-21 levels are decreased in bones from both old and Cx43-deficient mice [45]. Deletion 
of Cx43 from osteocytic cells results in reduced miR-21 and increased miR-218 expression 
levels; both changes are associated with increased apoptosis in other cell types [26]. In 
addition, deletion of miR21 in bone ex vivo is sufficient to increase osteocyte apoptosis. 
These findings indicate the cell autonomous requirement of Cx43 for the maintenance of 
miR-21/miR-218 levels in osteocytic cells and identify a new type of interaction not yet 
explored in osteocytic cells, by which connexins regulate miR expression.
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Cell-to-cell signaling via intercellular miR transfer
In addition to the well-established regulation of mRNA expression by miRs within the cell, 
recent studies have begun to demonstrate the role of miRs in mediating intercellular 
signaling through various mechanisms, involving both connexin channel-mediated transfer 
and EV-directed transport [5,31,32,39,47] (Fig. 1). Upon transfer, these miRs can alter 
mRNA expression and mediate downstream cellular effects in the recipient cell [31]. It was 
also recently discovered that miRs can function as ligands and directly interact with toll-like 
receptor (TLRs) [31], demonstrating yet another complexity associated with extracellular-
mediated miR signaling.
Connexin mediated miR transfer
Besides the interactions between connexin and miRs in the reciprocal regulation of their 
expression, gap junctions have been shown to transfer mature miRs between adjacent cells 
[5,31,47,48]. This has been demonstrated in a variety of cell types under both physiological 
and pathological conditions, as highlighted by Lim et al. [48] and in the review by Lemcke 
et al. [5]. Gap junctions have also been shown to transfer small interference (si)RNA, which 
are similar in size to miRs (20-30 nucleotides) [4]. Interestingly, gap junction-mediated 
transfer of siRNA appears to be dependent upon the connexin subtype, as evidenced by the 
findings that Cx43 gap junctions, but not Cx32 or Cx26 allowed cell-to-cell movement of 
siRNA. More recently, it was demonstrated that Cx43 with intact channel activity is required 
for miR intercellular transfer, with recipient cell having up to 30% of miR level of the donor 
cell [47]. This evidence suggests that connexin channels might also have specificity for 
transferring particular miRs. Additionally, AGO-bound miRs have been shown to pass 
between cells through gap junctions, where they can post-transcriptionally regulate target 
mRNAs in the recipient cells. It has also been hypothesized that these highly stable, AGO-
bound miRs can pass through hemichannels into the extracellular space, and later be 
transferred to a distant cells, in which miRs can regulate gene expression [31]. Although this 
gap junction mediated miR transfer has not been shown specifically in bone cells, these 
studies highlight the possible role of connexin channel-mediated miR transfer in the 
regulation of skeletal development and bone remodeling.
Extracellular vesicles modulate miR transfer
In addition to gap junction-mediated miR transfer, EVs have been shown to transport miRs 
that mediate intercellular communication [6,49]. EVs are released from numerous cell types 
[33], including many bone-associated cells such as mesenchymal stem cells (MSCs), 
osteoblast precursors, mature osteoblasts, osteocytes, and osteoclasts [7]. In recent years, 
EV-mediated miR transfer has gained the attention of numerous research fields; and an 
increasing number of studies have demonstrated the involvement of EV-derived miRs in 
regulating a vast array of cellular processes including proliferation, differentiation, activity, 
and survival [50]. During the process of plasma membrane budding miRs are incorporated 
into microvesicles and apoptotic bodies. Further, miRs are selectively packaged into MVBs, 
which are then released to the extracellular space as exosomes. Following extracellular 
release, these EV-contained miRs can then be taken up by adjacent or distant recipient cells 
through various uptake mechanisms, where they can regulate a variety of cellular processes 
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[32]. Several studies have shown the physiological importance of EV-mediated miR transfer, 
demonstrating miR-mediated regulation of gene expression in recipient cells and the 
downstream cellular effects associated with mRNA regulation [31].
Notably, an increasing number of studies have demonstrated the role of EV-derived miRs in 
controlling bone cells during skeletal development and homeostasis [7]. These miRs have 
been shown to regulate various aspects of bone remodeling from controlling bone cell 
differentiation to regulating cellular activity and survival. miRs have been shown to play a 
critical role in regulating key skeletal cell intracellular signaling including Wnt, insulin, 
TGF-β, and calcium signaling pathways [51]. Current work in the field is beginning to 
identify the effects of EVs derived from bone cells and determine the role of specific EV-
contained miRs in mediated these cellular effects. Specifically, bone cells including 
osteoblast precursors, mature osteoblasts, and mature osteoclasts have been shown to release 
miR-containing EVs that regulate bone remodeling through either stimulating or inhibiting 
bone cell differentiation and activity (recently reviewed by Xie and colleagues [7]).
In particular, osteoblast precursor-derived EVs have been shown to contain miRs involved in 
enhancing osteoblast differentiation (miR-199b [52], miR-218 [53], miR-181a [54], 
miR-196a [55,56], let-7 [57,58] family of miRs), as well as miRs that inhibit osteoblast 
differentiation (miR-135b [59,60], miR-204 [61], miR-855 [62]). Bone regulatory miRs have 
also been identified in EVs released by mature osteoblast including miRs involved in 
promoting osteoblast differentiation (let 7 [57,58], miR-335 [63], miR-378 [64], and 
miR-677 [51]) and miRs that inhibit osteoblast differentiation (miR-30d [65], miR-133b 
[66], miR-140 [67]). Further, EVs derived from both osteoblast precursors and mature 
osteoblasts have been shown to contain miRs that regulate osteoclast activity. Specifically, 
MSC-derived EVs containing miRs stimulate osteoclast differentiation (miR-148a [68]), and 
mature osteoblast-derived EV containing miRs (miR-503 [69]) inhibit osteoclast 
differentiation. Mature osteoclasts have also been shown to release EVs containing miR-214, 
which was found to both inhibit osteoblast differentiation and also stimulate osteoclast 
activity [70,71]. Thus, miRs can either increase or decrease the differentiation and function 
of osteoblasts and osteoclasts, depending on the particular miR and the stage of cell 
differentiation. Taken together, these findings illustrate the diverse roles of bone-derived EV-
contained miRs in controlling bone cell activity, demonstrating the importance intercellular 
miR transfer in mediating bone cell-cell signaling.
While promising, these findings demonstrate the need for future studies to identify the 
contribution of extracellular miR transfer in regulating skeletal development and bone 
remodeling. Thus, highlighting the potential involvement of both connexin channel-
mediated and EV directed miR transport as a means of modulating bone cell signaling under 
both normal and disease conditions.
Clinical applications/therapeutic potential
Due to the diverse regulatory capabilities of miRs, there is extensive therapeutic potential in 
understanding and modulating intercellular miR transfer. Extracellular miRs can serve as 
biomarkers for different disease conditions, allowing for less invasive and more specific 
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examination of different pathologies [27]. In particular for bone, a recent meta-analysis 
study showed that miR levels in tissue from individuals with osteosarcoma can predict the 
overall survival of the patients [72]. Further, cell-directed miR delivery appears to be a 
promising potential therapeutic treatment method for a vast array of diseases, through the 
use of both cell-based and cell-free delivery mechanisms [73,74].
The number of clinical trials using MSCs to treat various musculoskeletal conditions has 
drastically increased in recent years, including their beneficial use in treating osteoarthritis 
and other bone defects [75]. MSCs possess extensive potential to be used for cell-directed 
therapeutic treatment methods due to their phenotypic plasticity and the expression of key 
molecules involved in regulating osteogenesis, including miRs, which can be released in 
response to external stimuli [73]. In addition, MSCs can be used as vehicles for drug 
delivery because they can be easily manipulated and loaded particularly with miRs [76]. 
Moreover, MSCs express connexins that form channels able to mediate cell-to-cell transfer 
of miRs [77,78]. These findings highlight the potential therapeutic applications of using 
MSC cell based treatment methods and the importance of understanding and exploiting gap 
junction-mediated miR transfer.
In addition to direct cell-to-cell communication, recent studies have demonstrated the 
therapeutic potential of MSC-derived exosomes as a cell-free method to treat 
musculoskeletal conditions [74,75]. MSC-derived exosomes, as well as exosomes from other 
sources, selectively package miRs to regulate cellular processes and, in particular, 
osteogenic differentiation by potentially modifying RNA degradation, mRNA surveillance, 
RNA transport and Wnt signaling [62,74]. In addition, umbilical cord-derived MSCs were 
found to release factors that stimulated cartilage and bone repair in a calvaria critical defect 
rat model [79] and, similarly, exosomes released by human-induced pluripotent stem cell 
derived from MSCs were able to repair critical-sized bone defects in osteoporotic rats by 
stimulating both osteogenesis and angiogenesis [80]. Further, like MSCs, exosomes and 
other MSC-derived EVs have been used as vehicles to deliver drugs or bioactive molecules 
and genetic material including miRs [81]. Although there are still numerous unknowns with 
regards to exosomes as means of therapeutic treatment, the use of EVs is promising due to 
their highly stable nature and ability to transport a variety of important regulatory molecules, 
combined with the promising initial findings in studies testing their regenerative capabilities 
[82]. Exosomes, especially those derived from MSCs, appear to possess extensive 
therapeutic potential and merit further investigation, thus highlighting the importance of 
studying exosomal miR based delivery methods as a means to treat and prevent 
musculoskeletal diseases.
Conclusions
Recent findings have demonstrated that both connexins and miRs modulate the 
differentiation and function of bone cells, via complementary and opposing effects. Further, 
new light has been shed on the interaction between connexins and miRs, a very complex 
process that involves bidirectional miR- and connexin-mediated regulation of gene/protein 
expression. In addition, gap junction- and hemichannel-mediated miR transport to both 
adjacent and distant cells plays a role in cell-to-cell signaling in bone. Transport of miRs 
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and/or Cx43 via exosomes is another sophisticated way of interaction, which enhances the 
successful delivery of the molecules and also regulates molecular signaling in the recipient 
cell. In addition, the presence of Cx43 on the surface of exosomes facilitates the docking 
with the plasma membrane of a recipient cell and the delivery of the exosome cargo (in 
particular, of miRs).
In this review we have highlighted the relationship between miRs and connexins with 
emphasis on their known contribution to the regulation of skeletal development and bone 
remodeling. Numerous studies have demonstrated the critical roles of both miRs and 
connexins in maintaining proper bone cell signaling and skeletal homeostasis; however, 
there are still numerous unanswered questions regarding this area of research. These 
unknowns include the specific mechanisms that link and control the post-translational 
regulation of miRs and connexins and those that control intercellular miR transfer to both 
adjacent and distant cells.
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Fig. 1. Model for the proposed mechanisms of intercellular miRNA cell-to-cell transfer
Schematic representation of miR biogenesis (grey arrows), see text for more details. Upon 
completion of the biogenesis process, the mature RISC complex can regulate mRNA gene 
expression in the donor cell or can be transferred to adjacent or distant recipient cells to 
modulate mRNA expression by different manners (red arrows). Cell-to-cell transfer 
mechanisms include connexin-mediated transfer (via direct gap junctions or through 
hemichannels) and exosome-mediated transfer (via direct membrane fusion, clathrin-
mediated endocytosis, phagocytosis and micropinocytosis, receptor-ligand interaction, or 
connexin-mediated uptake). HC: hemichannel, GJC: gap junction channel, MVB: 
multivesicular body.
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